# ORM-1153

Source: https://onco.cc/drugs/orm-1153/  
OnCo record `orm-1153` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ORM-1153 is an experimental degrader-antibody conjugate from Orum Therapeutics, in phase 1 trials for CD123-positive acute myeloid leukaemia.

## Summary

ORM-1153 is a degrader-antibody conjugate from Orum Therapeutics. An anti-CD123 antibody joined by a cleavable beta-glucuronide linker to a GSPT1-degrading payload; once inside the cell it releases the payload, which kills the cancer cell by degrading GSPT1. Its furthest stage is phase 1, for CD123-positive acute myeloid leukaemia. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07809906 recruiting; first patient dosed per company release of 14 October 2026. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: ORM-1153
- Modality: Degrader-antibody conjugate
- Mechanism: An anti-CD123 antibody joined by a cleavable beta-glucuronide linker to a GSPT1-degrading payload; once inside the cell it releases the payload, which kills the cancer cell by degrading GSPT1.

## Sources

- Orum Therapeutics: orumrx.com: https://www.orumrx.com/news/orum-therapeutics-doses-fir-phase-1-trial-of-orm-1153-a-cd123-gspt1-degrader-antibody-conjugatest-patient-in
- Orum Therapeutics: orumrx.com: https://www.orumrx.com/news/orum-therapeutics-doses-fir-phase-1-trial-of-orm-1153-a-cd123-gspt1-degrader-antibody-conjugatest-patient-in
- Orum Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT07809906
- ClinicalTrials.gov: trials of ORM-1153: https://clinicaltrials.gov/search?intr=ORM-1153

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- targets: [CD123](https://onco.cc/targets/cd123/)
- companies: [Orum Therapeutics](https://onco.cc/companies/orum-therapeutics/)
- trials: [Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression](https://onco.cc/trials/nct07809906/)

---
JSON: https://onco.cc/api/v1/entities/orm-1153.json